These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25397526)

  • 1. Darunavir-based dual therapy in HIV experienced patients.
    Sterrantino G; Zaccarelli M; Di Biagio A; Rosi A; Bruzzone B; Cicconi P; Carli T; Biondi ML; Antinori A; Bartolozzi D; Penco G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19782. PubMed ID: 25397526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.
    Sterrantino G; Zaccarelli M; Di Biagio A; Biondi ML; Antinori A; Penco G;
    Infection; 2015 Jun; 43(3):339-43. PubMed ID: 25821204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients.
    Bernardino JI; Zamora FX; Valencia E; Moreno V; Vergas J; Tellez MJ; Estrada V; Gonzalez-Garcia J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19787. PubMed ID: 25397531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
    Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
    Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.
    Borghetti A; Mondi A; Piccoli B; Gagliardini R; Lamonica S; Ciccarelli N; D'Avino A; Pallavicini F; Cauda R; De Luca A; Fabbiani M; Di Giambenedetto S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19817. PubMed ID: 25397561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir-, raltegravir- or etravirine-containing antiretroviral therapy in the Western Cape Province of South Africa.
    Nuttall J; Pillay V
    S Afr Med J; 2018 Feb; 108(2):105-110. PubMed ID: 29429441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study.
    Portilla J; Arazo P; Crusells J; Pérez-Martínez L; Martínez-Madrid O; Boix V; Moreno J; Navarro V; Rubio T; Reus S; Galera C; Bernal E; Jover F; Amador C; Baño D; Merino E; Saiz-de-la-Hoya P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19803. PubMed ID: 25397547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
    Baroncelli S; Villani P; Galluzzo CM; Cavalli A; Volpe A; Francisci D; Vivarelli A; Sozio F; Tedeschi S; Cirioni O; Sighinolfi L; Cusato M; Pirillo MF; Weimer LE; Fragola V; Parruti G; Regazzi M; Floridia M
    Ther Drug Monit; 2013 Dec; 35(6):785-90. PubMed ID: 24061444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype.
    Salvo PF; Farinacci D; Ciccullo A; Borghi V; Rusconi S; Saracino A; Gennari W; Bruzzone B; Vicenti I; Callegaro A; Di Biagio A; Zazzi M; Di Giambenedetto S; Borghetti A
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
    Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment.
    Marcelin AG; Charpentier C; Wirden M; Descamps D; Calvez V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19744. PubMed ID: 25397489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.
    Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.